[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 188
Citations 0
Correction
May 28, 2019

Error in Table

JAMA Neurol. 2019;76(7):872. doi:10.1001/jamaneurol.2019.1177

In the Original Investigation titled “Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,”1 published online May 29, 2018, there was an error in Table 1. In the 14th row of the table, “Patients with acute medication overuse,” the number and percentage values should read “87 (20.2)” for the Placebo column; “39 (18.3)” for the Galcanezumab, 120 mg, column; and “42 (19.8)” for the Galcanezumab, 240 mg, column. This article was corrected online.

References
Reference
1.
Stauffer  VL, Dodick  DW, Zhang  Q, Carter  JN, Ailani  J, Conley  RR.  Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial.  JAMA Neurol. 2018;75(9):1080-1088.PubMedGoogle ScholarCrossref
×